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Barrett’s esophagus (BE) is a metaplastic change of the esophagus which is associated with
an increased risk of esophageal adenocarcinoma (EAC)1. The incidence of this cancer has
risen dramatically in the U.S. in the last 40 years,2 and prognosis for subjects presenting
with symptomatic EAC is dismal, with less than a 15% 5-year survival.3 For this reason,
strategies aimed at prevention figure prominently in societal guidelines for the care of BE.4
Currently, subjects found to have BE on upper endoscopy are often enrolled in endoscopic
surveillance programs. In these programs, subjects undergo surveillance endoscopy at
intervals governed by the degree of dysplasia found in random biopsies. Subjects developing
advanced disease become candidates for intervention, either by endoscopic or surgical
means.4 While it is intuitive that this approach might avert unresectable EAC, there are
several pragmatic issues that threaten the effectiveness of surveillance endoscopy5.
Dysplasia Detection in BE: A Clinical Conundrum
A major challenge implicit in our current approaches is the random nature of biopsies taken
at surveillance endoscopy. Current guidance suggests that biopsies be taken every 1–2 cm in
each of four quadrants throughout the length of the BE. Even when executed appropriately,
this approach samples a scant amount of the surface area, as little as 5% of the BE. Even
more disturbing is recent evidence suggesting that few endoscopists comply with
recommendations, and instead take markedly fewer biopsies than suggested per cm of BE.6
Unsurprisingly, multiple studies have suggested significant sampling error in BE
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surveillance programs, and surgical studies demonstrate that understaging of disease is
commonplace.7
Misinterpretation of histological specimens also lessens the efficacy of surveillance
programs. Given the minute amounts of tissue retrieved, the inherent difficulty is assigning
severity of dysplasia, and the confounding effect of any concurrent inflammation,
assignment of degrees of dysplasia is fraught with difficulty. This is especially true in the
case of low-grade dysplasia, a diagnosis for which agreement between pathologists is at best
moderate.8, 9 Because of variability of pathology reads, confirmation of dysplasia by a
second pathologist is recommended.4 These confirmatory readings add time and expense
Improvements in endoscopic therapy have further challenged the utility of traditional
endoscopic surveillance. In the past, the only available intervention was surgical
esophagectomy, and it was largely reserved for subjects with either adenocarcinoma, or as
one of several options for high-grade dysplasia. With the increased dissemination of
endoscopic ablative therapies, and the accumulating evidence that intervention in the setting
of high-grade dysplasia averts EAC,10, 11 endoscopic intervention is commonly performed
in high-grade dysplasia. Some practitioners are opting to perform ablation for lower degrees
of dysplasia as well.12 The need for histological interpretation of specimens obviates the
possibility of therapeutic intervention during the same endoscopic procedure. Instead, a two
procedure sequence, whereby the initial endoscopy is diagnostic and involves taking
biopsies, and the second is therapeutic, involving ablation or endoscopic mucosal resection
of diseased tissue, is performed.
Advanced Endoscopic Imaging in BE
Given the problems noted above with sampling error, difficulties with interpretation of
specimens, and the inability to treat dysplasia at the same endoscopic procedure that it is
discovered, there is substantial room for improvement in the care of subjects with BE. One
area of great interest is the use of endoscopic imaging techniques. These techniques may
either allow identification of areas of increased yield for endoscopic biopsies (so-called “red
flag” techniques), or may allow accurate interrogation of smaller areas of BE to assign a
degree of dysplasia. The technological challenges facing such modalities are daunting – they
must be accurate, easy to apply in the endoscopic setting, and require modest additional
training if they seek easy adoption.
A multitude of imaging techniques have been developed, and several have demonstrated
promise in cohort studies. The purpose of this review is to assess the current evidence
regarding a recently-described imaging modality for BE, angle-resolved low-coherence
interferometry (a/LCI)13. First, we briefly describe the theory behind a/LCI. Ex and in vivo
data regarding the use of the technology to detect dysplasia in the setting of BE are
reviewed. a/LCI is compared to other available and developing technologies for imaging in
BE, with respect to degree of resolution, depth of imaging and other characteristics. Finally,
we consider likely future developments in BE imaging generally, as well as with respect to
a/LCI specifically.
What is a/LCI and How Does it Work?
The basic premise of a/LCI is that light scattered by cell nuclei produces a pattern that is
both discernable and a function of their size and composition. By comparing data retrieved
from patient scans to patterns expected for various sized nuclei, a “best fit” is established,
allowing an estimate of average nuclear size. In this way, a/LCI takes advantage of a
seminal observation in oncogenesis: nuclei undergoing neoplastic degeneration become
larger and more pleomorphic on average than nuclei of non-neoplastic cells. Given this
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observation, a technology which accurately measures nuclear size in situ has the potential to
detect pre-cancerous change earlier and with greater accuracy than random biopsies. a/LCI
imaging has the additional benefit of being “depth-resolved.” This means that the device can
accurately assess nuclear size at multiple levels in the esophageal wall. As noted below, this
depth resolution is vital, since the depth most predictive of the presence of dysplasia
corresponds to the basal layer of epithelium. Below, we provide a more detailed description
of the a/LCI technique.
To allow assessment of sub-surface nuclei, a/LCI uses a technique called ‘coherence gating’
to achieve depth resolution, a similar process to that commonly used in optical coherence
tomography (OCT). This method allows selective detection of light originating from a
specific tissue layer by comparing it with a reference light using an interferometer. a/LCI
implements coherence gating by using light wavelengths in the near infrared region of the
spectrum. Depth resolution is achieved by having a portion of the light targeted to the tissue
while the remainder is used as a reference. Upon combining the scattered light returned from
the tissue with the reference light, the resulting interference pattern is detected by
wavelength and then processed to provide the depth resolved signal. In a/LCI, the coherence
gating process for depth resolution is combined with the high sensitivity of light scattering,
allowing measurements of nuclear morphology on a micron scale. Nuclear morphology
information is obtained by detecting the scattered light as a function of the angle of the
scattered light.
The a/LCI instrumentation consists of an optical engine which provides a light source and
receives the scattered light from the tissue, and a fiber probe which delivers and collects
light from the tissue (figure 1a)14. A specialized fiber probe has been developed which
delivers light using a polarization maintaining fiber, as knowledge of the light’s polarization
is important for enabling accurate light scattering analysis. The fiber probe also collects the
light scattered by the tissue using an imaging fiber bundle, with each fiber in the bundle
receiving light scattered at a specific angle. The probe incorporates an imaging lens at its tip
that is positioned such that each element in the fiber bundle collects light scattered at a
particular angle. The fiber probe is 2.3 meters long and approximately 2.5 millimeters wide,
enabling application through the accessory channel of most endoscopes (figure 1b), and is
enclosed in a plastic sheath. During operation of the a/LCI, the probe is passed through the
accessory channel and brought into contact with the epithelium. Data acquisition is initiated
by a foot pedal, and typically takes <40 milliseconds. During a typical interrogation of a
single 1 mm2 site, up to ten measurements are acquired in <1 second. There is a raised rim
on the tip of the probe, creating a transient tissue indentation that is obvious endoscopically
and allows targeting of a concurrent biopsy (figure 1c).
The a/LCI data are analyzed according to a well-documented procedure15. In brief, the data
are first segmented according to their depth of origin. For each depth segment, the angular
distribution of scattered light is analyzed through comparison to Mie theory, an analytical
model of scattering by homogeneous spherical objects. The comparison of the actual data to
the data expected for scatterers of given sizes allows a “best fit” analysis, yielding an
estimate of mean nuclear diameter. This measurement approach has been shown to produce
highly accurate nuclear measurements in a variety of cell and tissue types, with a typical
accuracy of 0.2–0.3 micrometers. Feasibility studies of a/LCI using animalmodels of
neoplasiain the esophagus demonstrate high sensitivity and specificity for discriminating
non-dysplastic from dysplastic tissues16. A follow on prospective study in the same animal
model examined over 80 tissue specimens and produced specificity and sensitivity > 90%17.
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Recently, a/LCI has been used to assess dysplasia in esophageal tissues. The first application
was an examination of ex vivo tissues using a portable instrument18. This study examined
tissues from just three patients, but showed good sensitivity and specificity when nuclear
morphology of dysplastic BE tissue was compared to that of gastric epithelium. While no
non-dysplastic BE tissue was encountered in these surgically resected esophageal
adenocarcinoma specimens, this study suggested potential for in vivo clinical application.
The first in vivo clinical a/LCI study compared measurements of nuclear morphology from
BE tissues with the histopathological evaluation of co-registered biopsies13. The study
enrolled 46 patients who were undergoing routine surveillance for BE. During the
procedure, the a/LCI fiber probe was applied via the accessory channel to non-nodular BE
tissue, and 3–6 sites selected randomly by the endoscopist were scanned. After each of the a/
LCI measurements, the probe was retracted and a co-registered biopsy was taken at the
imaging site. Figure 1b shows the esophageal mucosa under narrow band imaging (NBI)
immediately after application of the probe, and prior to biopsy. In total, 172 co-registered
optical and physical biopsies were acquired. The analysis was binary, separating the biopsies
as “dysplastic” (n = 13) or “non-dysplastic” (n = 159) according to histopathology. Of
available depth-resolved nuclear morphology measurements, the nuclear diameter from the
deep epithelium, 200 to 300 μm beneath the tissue surface, showed the best discrimination
for dysplasia (Figure 1c). The mean nuclear diameter from this layer was highly statistically
significant different between dysplastic and non-dysplastic tissues (P < 0.001). Evaluating
this metric using a receiver operating characteristic (ROC) curve, very good discrimination
was achieved, with an area under the curve (AUC) of 0.91. Based on this analysis, an
optimal decision line of nuclear diameter >11.84 μm was determined for classifying
dysplasia, yielding a sensitivity of 100% (13/13), and a specificity of 84% (134/159). The
positive and negative predictive values were found to be 34% (13/38) and 100% (134/134),
respectively. Further trials are underway both to confirm these intriguing results and to
continue to improve the diagnostic algorithm.
How Does a/LCI Compare to Other Advanced Imaging Strategies?
To assess the utility of a/LCI, it is useful to consider previous efforts using optical imaging
and spectroscopy methods in BE. A variety of optical techniques have been applied,
including autofluorescence, where short wavelength light is absorbed and re-emitted at
longer wavelengths, reflectance spectroscopy, which compares the different amounts of light
returned at several incident wavelengths, and Raman spectroscopy, which recovers
biochemical information by detecting subtle shifts in the frequency of returned light. The
strengths and weaknesses of these approaches and others were considered in a recent
review19. Ultimately, the sensitivity and specificity for detecting dysplasia will be a key
metric for utility. Figure 2 summarizes sensitivity and specificity of several recent studies
for discriminating normal from diseased BE tissues, including cancer, low grade and high
grade dysplasia. Below, we consider the various available advanced imaging technologies
with respect to their key operating characteristics: depth of penetration, imaging resolution,
need for contrast agents, and ease of use.
The a/LCI technique presents compelling characteristics for discriminating dysplasia in BE
because of its depth of penetration. The technique shares a common basis for depth
resolution with OCT, which has also been applied in BE20–23. Both technologies offer the
ability to probe tissue 1 millimeter, covering the full thickness of the epithelium. Importantly
from the clinician’s perspective, OCT technologies usually rely on an expert reader to
interpret the presence of dysplasia, unlike a/LCI, which reports nuclear diameter directly. To
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address this need, a recent study by Qi et al.22, used computer aided diagnosis to
retrospectively evaluate OCT images, showing improved sensitivity and specificity.
While most clinical OCT systems can only provide resolution of histological layers, a/LCI
is sensitive to sub-cellular structure which can be important for detecting early signs of
disease. Specifically, the a/LCI technique uses light scattering to recover information about
cell nuclei. Other approaches have shown sensitivity to cell nuclei, including light scattering
spectroscopy (LSS)24, 25 and elastic scattering spectroscopy (ESS)26, but these generally
lack the ability to obtain depth resolved information. LSS uses polarization to isolate
scattering from the surface layer of the epithelium to provide information on nuclear size.
ESS on the other hand, uses separated delivery and collection fibers to obtain a signal that
arises largely from the lamina propria, although the exact penetration depth can vary with
tissue type and probe geometry. The sensitivity of ESS to detect dysplasia is believed to
arise from variations in sub-cellular structures such as mitochondria in neoplasia.
Recent advances in endoscopic confocal microscopy have led to its application in assessing
dysplasia in BE using a fluorescent contrast agent, typically intravenously-administered
fluorescein 27, 28. In this approach, a probe-based confocal microscope is used to image the
mucosa, typically to a depth of 100–150 μm. As with OCT, an expert observer is required to
interpret these images. However, the use of a fluorescent contrast agent presents limitations
on the duration and repetition of imaging that are not found in label-free techniques.
In addition to the characteristics described above, the clinical ease of use must also be
considered when comparing these various imaging modalities. Interpretation of the high
resolution data generated by OCT and confocal microscopy may represent a challenge to
maintaining patient throughput, and requires training. Like a/LCI, OCT and confocal
microscopy also provide detail on only a small area of the mucosa per image. Recent studies
have documented efforts for wider-area scanning using OCT29, however, this approach
raises new challenges in handling, storage and interpretation of a tremendous volume of data
in a time- and cost-conscious manner
To summarize the capabilities of these various modalities, Figure 3 plots their depth
penetration and resolution graphically.
Future Directions
The a/LCI modality and several others discussed here have shown good ability to
discriminate dysplastic BE. However, this is not the only consideration for management of
BE. Other factors will also greatly influence the adoption of these technologies, including
the ease of use, reliability and cost, as well as its impact on the economics of surveillance.
Importantly, while several of the technologies have demonstrated proof of principle, data
substantiating improved clinically-important outcomes are rare.
It is quite possible that these techniques will be complementary, not competitive. For
instance, the ability to couple a wide-field, “red-flag” technique, such as autofluorescence,
with a modality that allows interrogation of smaller areas of suspect tissue, such as a/LCI,
may provide both the sensitivity and specificity clinicians’ desire. Even if these combined
modalities solely provided guidance to improve the yield of standard biopsies, such
improvement might be worth the time and effort. However, if the accuracy were high
enough to obviate the need to perform biopsies, much greater benefits would accrue,
including the cost savings of the biopsies and their interpretation, as well as the ability to
potentially perform therapeutic intervention at the same endoscopy as the diagnostic
examination. Such an approach would be premature based on presently-available data.
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However, given the myriad problems with our current approach, proving superiority of an
imaging-based approach to the current standard of care may not be difficult.
Future work with this modality will include validation of the data presented above, and
refinement of algorithms for discerning nuclear morphology. Additionally, an intuitive user
interface allowing graphic representation of nuclear size with immediate feedback as to the
presence of dysplasia and the quality of the signal being attained is necessary. Imaging of
larger surface areas of mucosa with a/LCI may be possible and would greatly enhance
utility. Finally, epithelial cancer of multiple organs, including colon, lung, and bladder,
share many of the same characteristics. Assessment of the potential utility of the device in
other organs both in and beyond the GI tract is underway.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Grant Support: This work was supported in part by the National Institutes of Health (National Cancer Institute
R01 CA138594).
Abbreviations
a/LCI angle-resolved low coherence interferometry
AUC area under the curve
BE Barrett’s esophagus
EAC esophageal adenocarcinoma
ESS elastic scattering spectroscopy
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NBI narrow-band imaging
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A) Simplified a/LCI system diagram. Red arrows indicate direction of light: delivery of light
using polarization maintaining (PM) fiber, collection of angular scattering using a fiber
bundle and the reference arm using single mode (SM) fiber. B) Images of a/LCI probe tip
next to a US dime for scale (left) and the mark left by the probe (right, arrow). C) a/LCI in
vivo clinical trial results. Points are colored according to their pathological diagnosis and
plotted as a function of their nuclear size and density as measured by a/LCI. Dashed line
indicates an optimal decision line identifying dysplastic tissue sites with a sensitivity of
100% (13/13) and a specificity of 84% (134/159). Adapted from Reference 13.
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Sensitivity and specificity relationship between in vivo BE dysplasia studies, plotted on an
ROC curve. Numbers indicated correspond to bibliographic reference number. This plot
shows the ability of the studies to differentiate LGD+HGD+Cancer from healthy tissue
when data are available. In the case of only HGD+ differentiation being performed, that
figure is used instead. Circle size indicates the number of patients in the study.
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Qualitative comparison of resolution/depth penetration for various endoscopic advanced
imaging modalities. The Y axis of the figure denotes the depth to which the imaging
modality can probe the tissue. The X axis denotes the degree of resolution, with modalities
on the right side of the figure providing a higher degree of resolution than those on the left.
Chevrons indicate the ability of a modality to penetrate deeper than indicated and increased
numbers of chevrons indicates increased penetration ability.
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